Trial Profile
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs VCL CB01 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Astellas Pharma
- 03 May 2017 Results presented at the 2017 American Transplant Congress
- 03 Aug 2016 Status changed from active, no longer recruiting to completed.
- 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.